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AbstrACt 
Introduction Pseudomonas aeruginosa (PA) has 
historically been one of the major causes of severe sepsis 
and death among neutropenic cancer patients. There has 
been a recent increase of multidrug-resistant PA (MDRPA) 
isolates that may determine a worse prognosis, particularly 
in immunosuppressed patients. The aim of this study is 
to establish the impact of antibiotic resistance on the 
outcome of neutropenic onco-haematological patients with 
PA bacteraemia, and to identify the risk factors for MDRPA 
bacteraemia and mortality.
Methods and analysis This is a retrospective, 
observational, multicentre, international study. All episodes 
of PA bacteraemia occurring in neutropenic onco-
haematological patients followed up at the participating 
centres from 1 January 2006 to 31 May 2018 will be 
retrospectively reviewed. The primary end point will be 
overall case-fatality rate within 30 days of onset of PA 
bacteraemia. The secondary end points will be to describe 
the following: the incidence and risk factors for multidrug-
resistant and extremely drug-resistant PA bacteraemia 
(by comparing the episodes due to susceptible PA with 
those produced by MDRPA), the efficacy of ceftolozane/
tazobactam, the rates of persistent bacteraemia and 
bacteraemia relapse and the risk factors for very early 
(48 hours), early (7 days) and overall (30 days) case-fatality 
rates.
Ethics and dissemination The Clinical Research Ethics 
Committee of Bellvitge University Hospital approved 
the protocol of the study at the primary site. To protect 
personal privacy, identifying information of each patient in 
the electronic database will be encrypted. The processing 
of the patients’ personal data collected in the study will 
comply with the Spanish Data Protection Act of 1998 and 
with the European Directive on the privacy of data. All 
data collected, stored and processed will be anonymised. 
Results will be reported at conferences and in peer-
reviewed publications.
IntroduCtIon
During the last 10 years the aetiology of blood-
stream infections (BSI) among neutropenic 
cancer patients has significantly changed. 
Several studies have shown an increase of BSI 
caused by Gram-negative bacilli that may be 
explained by the use of reduced-intensive 
chemotherapy regimens, associated to less 
strengths  and limitations of this study
 ► The multicentre design of the study will allow the 
recording of a large number of episodes.
 ► The international and multicentre design will provide 
representative results regarding the current epide-
miology of Pseudomonas aeruginosa bacteraemia in 
onco-haematological patients worldwide.
 ► Information will be provided on risk factors for resis-
tance acquisition and their impact on mortality in the 
current era of multidrug resistance.
 ► Due to the retrospective design some information 
may be lost.
 ► We may not be able to control for certain measured 
and unmeasured confounders.
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severe mucositis, and by the discontinuation of quinolone 
prophylaxis in some institutions.1 2 
Pseudomonas aeruginosa (PA) has historically been one 
of the major causes of severe sepsis and death among 
neutropenic cancer patients. BSIs due to multidrug-re-
sistant PA (MDRPA) and multidrug-resistant Enterobacte-
riaceae are increasing worldwide and are both associated 
with poorer outcomes, particularly in immunocompro-
mised patients.3–5
There is limited published data describing the char-
acteristics of PA infections in patients with cancer in 
this era of widespread antimicrobial resistance.5–7 More-
over, data regarding BSIs in neutropenic patients with 
solid tumours are particularly scarce.8 In addition, very 
little is known about the impact of the introduction 
of the new broad-spectrum beta-lactam plus beta-lact-
amase inhibitor combinations (such as ceftolozane/
tazobactam) in the therapeutic armamentarium for the 
treatment of BSI due to MDRPA in neutropenic cancer 
patients.
Identifying the risk factors for infection due to MDRPA 
in neutropenic cancer patients could help physicians to 
recognise patients at risk more rapidly. Therefore, the 
early administration of a broader empirical antibiotic 
therapy in these high-risk patients might have a positive 
influence on their outcomes. In the present international 
study, we aim to determine the impact of antibiotic resis-
tance on outcomes in neutropenic cancer patients with PA 
bacteraemia in the current era of widespread antimicro-
bial resistance, and also to identify predisposing factors 
for multidrug resistance and mortality. For this purpose, 
we will compare episodes due to susceptible PA with those 
produced by MDRPA, and we will compare patients who 
died with those who survived.
objECtIvEs of thE study
Primary objective
 ► To determine the impact of antibiotic resistance on 
outcomes in neutropenic cancer patients with PA 
bacteraemia, measured by all-cause case-fatality rate 
at 30 days.
secondary objectives
 ► To assess the prevalence of multidrug and extremely 
drug resistance (XDR) among PA isolates causing 
bacteraemia.
 ► To identify the risk factors for infection due to multi-
drug-resistant (MDR) and XDR PA.
 ► To assess the efficacy of the new beta-lactam ceftolo-
zane/tazobactam for the treatment of bacteraemia 
due to PA.
 ► To estimate the cumulative incidence rates of persis-
tent bacteraemia, bacteraemia relapse and other 
complications at 30 days.
 ► To identify the risk factors for very early (48 hours), 
early (7 days) and all-cause (30 days) case-fatality rates.
MEthods And AnAlysIs
study design
This is an international, multicentre, retrospective, 
observational cohort study involving neutropenic cancer 
patients diagnosed with PA bacteraemia followed up at 
any of the participating centres during the study period. 
The study will be conducted in accordance with the 
STrengthening the Reporting of OBservational studies in 
Epidemiology  (STROBE) recommendations (see research 
checklist).9
study population
Data will be collected on all-adult (≥18 years) onco-hae-
matological neutropenic patients diagnosed with at least 
one episode of PA bacteraemia during the study period.
study period
Participating centres will retrospectively review all 
episodes of PA bacteraemia occurring in neutropenic 
onco-haematological patients from 1 January 2006 to 
31 May 2018.
setting
The study will be conducted at 34 centres from 12 different 
countries: Spain (14), Turkey (4), Brazil (3), Italy (3), 
Argentina (2), Germany (2), Chile (1), Colombia (1), 
Lebanon (1), Slovakia (1), Switzerland (1) and UK (1).
selection of cases
Patients will be identified from previous retrospective and 
prospective databases or from the records of the microbi-
ology laboratory at each hospital.
Inclusion criteria
1. Adult patients (≥18 years).
2. Patients diagnosed with a haematological malignancy 
and/or haematopoietic stem cell transplant recipients, 
or with solid organ tumour.
3. The presence of neutropenia (<500 neutrophils/mm3) 
at the bacteraemia onset.
4. Episodes of monomicrobial PA bacteraemia or poly-
microbial bacteraemia in which PA is one of the eti-
ological agents, including community, healthcare and 
nosocomial infections.
5. Subsequent episodes of PA bacteraemia diagnosed in 
a patient may be included if the interval between them 
is 30 days.
Exclusion criteria
Patients with any of the following will be excluded from 
the study:
1. Unavailability of key data (empirical and targeted ther-
apy and vital status at 30 days).
2. Episodes occurring in non-neutropenic cancer pa-
tients.
3. Episodes occurring outside the study period.
4. Age<18 years old.
data collection
Patients’ data will be collected retrospectively. These data 
will be obtained from various sources, including patients’ 
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electronic records, patients’ notes, the hospital laboratory 
systems and the hospital patient administration system.
The following data will be collected for all cases: sex, 
age, type of underlying disease and comorbidities, under-
lying malignancy status, severity of the episode of febrile 
neutropenia according to the Multinational Association 
of Supportive Care in Cancer (MASCC) index score,10 
place of acquisition of infection,11 source of bacteraemia, 
bacteraemia source control status, clinical and microbi-
ological data, total duration of neutropenia (including 
days of neutropenia before and after BSI onset), prior 
therapies received (including antibiotics and immuno-
suppressive treatments), empirical and definitive anti-
microbial therapy, doses and duration of each antibiotic 
therapy, need for intensive care unit admission and 
mechanical ventilation, persistent bacteraemia, relapse 
of bacteraemia, colonisation and/or superinfection by 
resistant organisms, development of other complications, 
48 hours, 7-day and 30-day case-fatality rates.
Patient and public involvement
Patients and public will not be involved in the design or 
development of the study.
definitions
Empirical antibiotic therapy: Antimicrobial therapy ad-
ministered before reception of definitive antibiotic 
susceptibility results.
Definitive antibiotic therapy: antimicrobial therapy ad-
ministered according to definitive antibiotic suscepti-
bility results.
Adequate antibiotic therapy: therapy based on at least one 
in vitro active antibiotic against the PA strain causing 
the infection. Monotherapy with an active aminoglyco-
side will be considered adequate.
Persistent bacteraemia: persistent BSI beyond the first 
48 hours of adequate antibiotic therapy.
Bacteraemia relapse: relapse of BSI within 7 days of treat-
ment discontinuation.
Microbiological studies
Clinical samples are processed at the microbiology labo-
ratories of each participating centre in accordance with 
standard operating procedures. PA will be identified using 
standard microbiological techniques at each centre. In 
vitro susceptibility is determined according to the Euro-
pean Committee on Antimicrobial Susceptibility Testing 
(EUCAST) recommendations.12 The specific mechanisms 
of resistance will be provided when possible, according to 
molecular analyses. Phenotype stratification of PA isolates 
is made in accordance with recent standard definitions.13 
MDRPA: the isolate is non-susceptible to at least one agent 
in three or more of the following antimicrobial catego-
ries: aminoglycosides, antipseudomonal carbapenems, 
antipseudomonal fluoroquinolones, antipseudomonal 
cephalosporins, antipseudomonal penicillins+beta lact-
amase-inhibitors, monobactams, fosfomycin, polymyxins. 
XDR PA: the isolate is non-susceptible to at least one 
agent in all but two or fewer of the antimicrobial catego-
ries listed earlier. PDR PA: the isolate is non-susceptible to 
all antimicrobial agents listed earlier.
Participant timeline
The follow-up period will last 1 month after bacteraemia 
onset.
study outcomes and endpoint assessment
Primary endpoint
 ► Case-fatality rate at 30 days from onset of bacteraemia.
Secondary endpoints
 ► 48 hours and 7-day case-fatality rates from onset of 
bacteraemia.
 ► Prevalence and risk factors for multidrug and 
extremely drug resistance acquisition
 ► Efficacy of ceftolozane/tazobactam for the treatment 
of bacteraemia due to PA, measured by all-cause 
(30 days) case-fatality rate.
 ► Rate of persistent bacteraemia beyond the first 
48 hours of adequate antibiotic therapy.
 ► Rate of bacteraemia relapse within 14 days of treat-
ment discontinuation.
 ► Rate of other complications within 30 days from bacte-
raemia onset (eg, ICU admission).
sample size
The total number of episodes of PA bacteraemia in the 
participating centres during the study period will deter-
mine the sample size. According to the previous experi-
ence of each participating centre, we expect to record 
around 1000 episodes during the study period, allowing 
the estimation of 95% CIs with a 3% margin of error.
statistical analysis
Baseline characteristics of participants will be described 
using mean and SD for continuous variables and frequen-
cies for categorical variables. Cumulative incidence rate 
will be calculated as the number of events divided by 
participants at risk at bacteraemia onset. The 95% CI 
will be estimated using normal approximation for large 
incidence values (above 10%) and Poisson approxima-
tion for small ones. A set of demographic and clinical 
factors will be analysed to quantify their association with 
the following outcomes: 30-day mortality, MDR and XDR. 
To do so, a logistic regression model will be used, and 
OR with CIs will be presented. Patients’ mortality survival 
functions will be estimated using Kaplan-Meier curves 
and compared using the log-rank test. Moreover, survival 
functions will also be analysed at 7, 14 and 30 days. No 
missing data are expected regarding the main outcomes, 
since unavailability of related data is an exclusion crite-
rion. With sensitivity purposes, the main analyses will be 
replicated in patients with high-risk bacteraemia, such 
as those with pneumonia. Model assumptions, condi-
tions and residuals will be assessed. A p value<0.05 will 
be considered statistically significant. The analysis will be 
performed using R software (R V.3.2.5).
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Ethical issues
The study has been approved by the Comité Ético de Inves-
tigación Clínica del Hospital Universitari de Bellvitge (Insti-
tutional Review Board of Clinical Research, Bellvitge 
University Hospital). A list with the participating centres 
that obtained the approval by their institutional review 
board, and the centres that did not need the approval 
is provided in the online Supplementary file 1. To 
protect personal privacy, identifying information of each 
patient in the electronic database will be encrypted. The 
processing of the patients’ personal data collected in this 
study shall comply with the Data Protection Act 1998 and 
with the European Directive on the privacy of data. All 
data collected, stored and processed will be anonymised. 
The investigator/research lead at each site will guar-
antee that all team members or other persons involved 
at the site in question will respect the confidentiality of 
any information concerning the study patients. The Clin-
ical Research Ethics Committee has waived the need for 
informed consent due to the retrospective nature of the 
study.
PublICAtIon PlAn
Results will be reported at conferences and in peer-re-
viewed publications. The first publication will be based 
on data from all sites, and will be analysed as stipulated in 
the protocol with supervision by statisticians. Any formal 
presentation or publication of data collected from this 
study will be considered as a joint publication by the 
participating investigators and will follow the recom-
mendations of the International Committee of Medical 
Journal Editors.
dIsCussIon
In recent years, a trend towards an increase of Gram-neg-
ative BSI among neutropenic cancer patients has been 
reported.1 Neutropenic patients with onco-haematolog-
ical malignancies are considered a population at high 
risk for MDR bacterial infections because of their need 
for long hospitalisation and significant antibiotic pres-
sure.14 In this regard, recent studies have described an 
alarming increase in the incidence of bacteraemia due 
to extended-spectrum beta-lactamase-producing and 
carbapenem-resistant Enterobacteriaceae among neutro-
penic cancer patients, which may substantially impair 
patients’ outcomes.2 15 16
Classically, PA has been one of the leading causes of 
bacteraemia in neutropenic patients with haematological 
malignancies and solid tumours, and is associated with 
poor prognosis.8 17–19 In recent years, particular attention 
has been paid to the emergence of MDR Enterobacteriaceae, 
and data on the current epidemiology of PA bacteraemia 
and the impact of antibiotic resistance in this high-risk 
population are lacking. The existing literature is based 
on heterogeneous studies some of which present meth-
odological shortcomings.5–7 14 20 21
First, most of the studies have a retrospective and single-
centre design.5 6 14 20 21 Only three prospective studies 
have addressed this issue and all have a small sample 
size; in addition, the fact they were conducted more than 
7 years ago does not allow the extrapolation of the data to 
the current era of multidrug resistance.5 6 16 In addition, 
the few studies with a multicentre design have included 
only centres from the same country, and therefore, the 
results may not be representative of different geograph-
ical areas.3 7 Second, some studies include a diverse 
variety of infections due to PA, and only a few focus exclu-
sively on patients with PA bacteraemia.5 7 14 20 Third, only 
two recent studies describe the current risk factors for 
MDR-PA acquisition and for mortality in this high-risk 
population.7 20 However, one of these studies is a retro-
spective, single-centre Korean study involving only paedi-
atric patients,20 and the other is a retrospective, 3-centre 
study limited to the city of Athens.7
The published data comparing the efficacy of combined 
empirical antibiotic treatment including two active 
antipseudomonal agents versus monotherapy in patients 
with febrile neutropenia are controversial. The aim of 
empirical combination therapy is to provide extend-
ed-spectrum coverage against MDR organisms in high-risk 
patients, since a delayed initiation of adequate antibiotic 
treatment has been associated with poorer outcomes, 
particularly in patients with PA bacteraemia.5 7 20 21 
However, an important meta-analysis published in 2013 
was unable to show any advantage of combination anti-
biotic treatment in cancer patients with neutropenia.22 
Nonetheless, in a recently published report, Tofas et al 
found a trend towards improved survival with combina-
tion therapy in this setting.7 Clearly, more studies are 
needed to analyse whether combination therapy could be 
beneficial in the current era of multidrug resistance.
Clinical experience with the use of new broad-spec-
trum beta-lactams to treat MDR-PA infections, such as 
ceftolozane/tazobactam, is gradually accumulating in the 
general population. However, little is known about its use 
for the treatment of MDR-PA bacteraemia in neutropenic 
cancer patients.
The present study aims to identify the current impact 
of the antibiotic resistance on outcomes in neutropenic 
patients with PA bacteraemia, and to determine the risk 
factors associated with multidrug resistance and mortality. 
We will also assess the efficacy of new broad-spectrum 
beta-lactams against MDR-PA strains, since alternative 
treatments are urgently needed in this vulnerable popula-
tion. This study shall provide useful information for physi-
cians’ daily clinical practice, who need to rapidly identify 
patients at high risk for MDR-PA bacteraemia, to be able 
to promptly initiate effective antimicrobial therapy and 
improve patients’ outcomes.
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